Leukemias, lymphomas, and other hematologic cancers:
Indications for EMPLICITI:
Treatment of multiple myeloma: in combination with lenalidomide and dexamethasone in patients who have received 1–3 prior therapies; or in combination with pomalidomide and dexamethasone in patients who have received ≥2 prior therapies including lenalidomide and a proteasome inhibitor.
Give by IV infusion at initial rate of 0.5mL/min (10mg/kg dose) or 3mL/min (20mg/kg dose); may increase stepwise if no reactions develop (see full labeling); max rate 5mL/min. In combination with lenalidomide and dexamethasone: 10mg/kg every week for the first 2 cycles then every 2 weeks thereafter. In combination with pomalidomide and dexamethasone: 10mg/kg every week for first 2 cycles; then starting at cycle 3, give 20mg/kg every 4 weeks. Both: continue until disease progression or unacceptable toxicity. For dosing schedule of lenalidomide, pomalidomide, and dexamethasone: see full labeling. Premedicate with dexamethasone, H1 blocker, H2 blocker, and acetaminophen before each infusion. Dose modifications: see full labeling.
Consult lenalidomide, pomalidomide, and dexamethasone prescribing information for contraindications before starting therapy (eg, pregnancy).
Interrupt infusion if Grade ≥2 infusion reactions occur and manage appropriately. Monitor for development of infections and treat promptly. Monitor for second primary malignancies. Monitor liver function periodically; discontinue if Grade ≥3 elevation of liver enzymes occur; consider resuming after return to baseline values. Pregnancy: not studied. Nursing mothers: not recommended.
SLAMF7-directed immunostimulatory antibody.
May interfere with correct response classification in SPEP and serum immunofixation assays.
Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, hyperglycemia.
For lenalidomide, pomalidomide, and dexamethasone specific dosing and safety information, refer to their respective full labeling.